Oftalmol Zh.2011;2:35-38.

Full text Pdf 



Yakimenko S. A., Buznyk O. I., Shyshkova G. G.

Odessa, Ukraine

There was evaluated the influence of 0.15 % solution of hyaluronic acid («Oxyal») on the subjective and objective symptoms of the dry eye syndrome (DES) in patients with outcomes of severe eye burns in whom ocular and eyelid surface were covered with oral mucous grafts.

It was a randomized, crossover study where patients who finished treatment by both preparations were added («Oxyal» and placebo — saline). The treatment period for each preparation was 1 week. At the beginning of the study, in 1 and 2 weeks frequency of side effects and symptoms of DES were assessed by the DES questionnaire (OSDI).

The application of «ОхуаЬ led to significant improvement ofthe DES symptoms (p = 0.016, 95 % reliable interval is from 11.3 to -1.2) and was well tolerated by the patients (difference in side effects frequency was non-significant compared with placebo — p = 0.235).

Thus, 0.15 % solution of hyaluronic acid («Oxyal») is safe and effective preparation for treatment of severe DES in patents with consequence of eye burns in whom ocular and eyelid surface are covered with oral mucous grafts.



1.Бржеский В. В., Сомов Е. Е. Роговично-конъюнктивальный ксероз. СПб., 2003. 119 с.

2.Егорова Г. Б., Зуева Ю. С., Митичкина Т. С. Оксиал как средство медикаментозной коррекции синдрома сухого глаза при ношении контактных линз // Рус. мед. журн. — 2010. — Т.11(№ 1). — С. 14-16.

3.Якименко С. А., Бузник О. Г, Чаланова Р. I. и др.. Частота і результати лікування синдрому сухого ока у хворих з наслідками важких опіків очей гелем «Відісік» і краплями «Штучна сльоза» // І Всеукр. конф. «Фармакотерапія в офтальмології», тези. — Харків, 2007. —С. 106-108.

4.Aragona P., Di Stefano G., Ferreri F., et al. Sodium hyaluronate eye drops of different osmolality for the treatment of dry eye in Sjogren's syndrome patients // Br. J. Ophthalmol. — 2002. — Vol. 86. — P. 879- 884.

5.Balazs E. A., Armand G. Glycosaminoglycans and proteoglycans of ocular tissues. In: Varma R. S., Varma R. (eds) Glycosaminoglycans and Proteoglycans in Physiological and Pathological Processes of Body Systems. Karger: Basle. — 1982. — P. 480- 489.

6.Begley C. G., Chalmers R. L., Mitchell G. L., et al. Characterization of ocular surface symptoms from optometric practices in North America // Cornea. — 2001. — Vol. 20(6). — P. 610-618.

7.Condon P., McEwan C. G., "Wight M. et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0,1 % (w/v) sodium hyaluronate solution (Fermavisc®) in the treatment of dry eye syndrome // Br. J. Ophthalmol. 1999. — Vol. 83. —P. 1121-1124.

8.DeLuise V. P., Peterson W. S. The use of topical sodium hyaluronate (Healon) in the management of refractory dry eye syndrome // Ann. Ophthalmol. — 1984. — Vol. 16. — P. 823-824.

9.Fukuda M., Miyamoto Y., Miyara Y. et al. Hyaluronic acid in tear fluid and its synthesis by corneal epithelial cells // Asia-Pacific J. Ophthalmol. 1998. — Vol. 10. — P. 20- 22.

10.McDonald C. C., Kaye S. B., Figueiredo F. C. et al. A randomised, crossover, multicentre study to compare the performance of 0,1 % (w/v) sodium hyaluronate with 1,4 % (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. — Eye. — 2002. — Vol. 16. — P. 601- 607.

11.Sand B. B., Marner K., Nom M. S. Sodium hyaluronate in the treatment of keratoconjunctivitis sicca // Acta Ophthalmol. — 1989. — Vol. 67. — P. 181-183.

12.Vogela R., Crockett R. S., Odenc N. et al. Demonstration of Efficacy in the Treatment of Dry Eye Disease with 0,18 % Sodium Hyaluronate Ophthalmic Solution (Vismed, Re¬jena) // Am. J. Ophthalmol. — 2010. — Vol. 149 (4). —P. 594-601.